Tumor Mitotic Rate Is a More Powerful Prognostic Indicator than Ulceration in Patients with Primary Cutaneous Melanoma

Size: px
Start display at page:

Download "Tumor Mitotic Rate Is a More Powerful Prognostic Indicator than Ulceration in Patients with Primary Cutaneous Melanoma"

Transcription

1 1488 Tumor Mitotic Rate Is a More Powerful Prognostic Indicator than Ulceration in Patients with Primary Cutaneous Melanoma An Analysis of 3661 Patients from a Single Center Manuela F. Azzola, M.D. 1 Helen M. Shaw, Ph.D. 1,2 John F. Thompson, M.D. 1,2 Seng-jaw Soong, Ph.D. 3 Richard A. Scolyer, M.B.B.S. 4 Geoffrey F. Watson, M.B.B.S. 4 Marjorie H. Colman, B.Sc. 1 Yuting Zhang, M.Sc. 3 1 Sydney Melanoma Unit, Royal Prince Alfred Hospital, Camperdown, New South Wales, Australia. 2 Department of Surgery, University of Sydney, Sydney, New South Wales, Australia. 3 Department of Biostatistics, University of Alabama at Birmingham, Birmingham, Alabama. 4 Department of Anatomical Pathology, Royal Prince Alfred Hospital, Camperdown, New South Wales, Australia. BACKGROUND. The current study was performed to determine whether tumor mitotic rate (TMR) is a useful, independent prognostic factor in patients with localized cutaneous melanoma. METHODS. From the Sydney Melanoma Unit database, 3661 patients with complete clinical information and details of primary tumor thickness, ulcerative state, and TMR were studied. TMR was expressed as mitoses per mm 2 in the dermal part of the tumor in which most mitoses were seen, as recommended in the 1982 revision of the 1972 Sydney classification of malignant melanoma. To determine which was the more prognostically useful method of grouping TMR, two separate methods (A and B) were used. Factors predicting melanoma-specific survival were analyzed using the Cox proportional hazards regression model. RESULTS. Patients with a TMR of 0 mitoses/mm 2 had a significantly better survival than those with 1 mitosis/mm 2 (P ) but no significant survival differences were recorded for the stepwise increases from 1 2, 2 3, 3 4, and 4 5/mm 2. Tumor thickness, ulceration, and TMR were closely correlated, whether TMR was grouped using Method A (0, 1 4, 5 10, and 11 mitoses/mm 2 ) or Method B (0 1, 2 4, and 5 mitoses/mm 2 ). However, Cox regression analysis indicated that the TMR was a highly significant independent prognostic factor, particularly when grouped according to Method A, in which it was second only to tumor thickness as the most powerful predictor of survival (P ). CONCLUSIONS. TMR is an important independent predictor of survival for melanoma patients. If confirmed by studies from other centers, it has the potential to further improve the accuracy of melanoma staging, as well as to define more rigidly the risk categories for patients entering clinical trials. Cancer 2003;97: American Cancer Society. DOI /cncr KEYWORDS: primary melanoma, tumor mitotic rate, thickness, ulceration, prognosis, staging. The financial support of the Melanoma Foundation of The University of Sydney and The Melanoma and Skin Cancer Research Institute is gratefully acknowledged. Address for reprints: Helen M. Shaw, Ph.D., Sydney Melanoma Unit, Royal Prince Alfred Hospital, Missenden Road, Camperdown, New South Wales, 2050, Australia; Fax: ; helen@mel.rpa.cs.nsw.gov.au Received June 11, 2002; revision received October 21, 2002; accepted October 24, The prognosis for a patient who presents with a primary cutaneous melanoma depends on a number of variables, principally tumor thickness but to a lesser extent on other features of the primary tumor such as ulceration, Clark level and anatomic site, and the patient s age and gender. The relative importance of these prognostic variables has been the subject of many studies over the past 25 years using progressively more sophisticated statistical techniques. Methods of analyzing multivariate data with the logistic model were introduced by Walker and Duncan in In 1970, Cox 2 further illustrated how this model could be used and subsequently 2003 American Cancer Society

2 Mitotic Rate and Prognosis in Melanoma/Azzola et al introduced the proportional hazards regression model in Beginning in the late 1970s and continuing into the 1980s, both models were used to study outcomes in patients with melanoma, particularly to assess the importance of a range of prognostic factors. These models helped, to varying extents, to clarify the relative roles and interdependencies of these various factors. Nevertheless, in the opinion of Vollmer in his seminal review of this subject published in 1989, 4 these models had at that time failed to provide optimal understanding of prognosis for patients with this disease. These reservations are still applicable. Indeed, when the recent literature on this topic is perused, one is struck by the remarkable discrepancies between centers that exist as to which variables have independent predictive value. Although it is apparent that tumor thickness is the principal determinant of prognosis for localized cutaneous melanoma in nearly all large studies, there is a failure of other factors to have consistent independent value, mainly because of their secondary correlation with tumor thickness. 4 Using the Cox proportional hazards regression model, Balch et al. 5 analyzed factors predicting melanoma-specific survival among 17,600 patients with cutaneous melanoma to validate proposed major revisions to the American Joint Committee on Cancer (AJCC) staging system. It was found that in the T category, tumor thickness and ulceration were the most powerful predictors of survival. Based on this large analysis, both these features were incorporated into the new staging system. 6 However, the impact of tumor mitotic rate (TMR) was not assessed in that study. Mitotic rate has been variously reported as either having or not having independent prognostic significance, but no major study to date has considered in detail its complex interdependency on tumor thickness and ulceration. Accordingly, the records of a large cohort of patients with invasive cutaneous melanoma treated at the Sydney Melanoma Unit (SMU) were analyzed to evaluate the possible independent prognostic importance of TMR, mindful of its close relationship with these other two dominant prognostic variables. The primary objective of this study was to determine whether TMR was a useful independent prognostic factor. This question has obvious relevance not only for individual patients, but for assignment of risk status in groups of patients entering clinical trials. MATERIALS AND METHODS The SMU database contains extensive clinical and pathologic details of nearly 20,000 patients treated for melanoma from 1960 to 2002 at Royal Prince Alfred, St. Vincents, and Sydney Hospitals in Sydney, Australia. First, the patients selected from this database for the current study were those who had been treated definitively (i.e., by a wide excision with either primary closure or a skin graft) from the outset at the SMU. Patients initially treated elsewhere and presenting to the SMU later in the course of their disease because of recurrence were excluded from this study to minimize referral bias. Second, patients had only one primary, invasive, cutaneous melanoma. Third, patients had localized disease (i.e., pathologic Stage I or II of the American Joint Committee on Cancer (AJCC)/International Union Against Cancer (UICC)pTNM pathologic classification). Finally, primary lesion pathology was reviewed by histopathologists from the Department of Anatomical Pathology at the Royal Prince Alfred Hospital, who were experienced in the diagnosis and reporting of melanocytic skin lesions. Pathologic details, assessed at the time of first definitive treatment of the patient s primary lesion, included the thickness, ulcerative state, and the TMR of the primary tumor, with the latter being expressed as the number of mitoses/mm 2 in the dermal area of the tumor in which most mitoses were noted. This method of assessing TMR was adopted after 1982, upon the recommendation of the participants of the 1982 Pathology Workshop 7 which revised the 1972 Sydney Classification of Malignant Melanoma. 8 In this original classification, the number of mitoses in at least 10 high power fields (HPF) over the entire lesion was counted and then expressed as the average number of mitoses/hpf. The 1982 Workshop participants considered that their revised method of assessing TMR, with results expressed as mitoses/mm 2, would be independent of the particular microscope and magnification used and therefore results obtained in different parts of the world would become more comparable. A total of 3661 patients satisfied the selection criteria outlined above. In patients with intermediate to high-risk lesions (i.e., lesions 1.5 mm in thickness), elective lymph node dissection usually was performed before Since then, a sentinel lymph node biopsy procedure has been offered to 645 patients with tumors thicker than 1.0 mm in the context of various clinical trials. We specify the criteria used for the three key pathologic variables with their codings, codings for four other putative prognostic variables, and methods of statistical analysis. Tumor Thickness This was measured according to the method of Breslow 9 as the vertical distance between the upper level of the granular layer of the epidermis and the deepest part of the tumor. Deeper tumors growing laterally from hair follicles were ignored. When ulcer-

3 1490 CANCER March 15, 2003 / Volume 97 / Number 6 ation was present, the thickness of the tumor was measured to the level of the base of the surface exudate. Thickness groupings were those recently recommended for the revised staging system of the AJCC 6 : Group 1, 1.0 mm or less; Group 2, mm; Group 3, mm; and Group 4, 4.00 mm or greater. Ulceration Ulceration in melanomas is not a homogenous phenomenon, with some types of ulceration having more prognostic significance than others. Three types of ulceration are recognized: infiltrative (erosive), attenuative (tumorigenic), and traumatic. The first two types of ulceration have been recognized by our pathologists to be prognostically significant. This is in contrast to traumatic ulceration, which has been generally accepted as prognostically irrelevant since being first described as such in 1953 by Thompkins 10 and by Peterson et al. 11 in Infiltrative ulceration is seen in melanomas displaying epidermal invasion. Although epidermal invasion is seen in melanomas of the superficial spreading histogenetic type, it is also commonly seen in the central region of melanomas of other histogenetic types, particularly as they progress. The invading cells permeate the epidermal cells, disrupting spinous layer cohesion, to eventually result in ulceration. Attenuative ulceration tends to occur in large nodular melanomas that lack epidermal invasion, but their expansile growth stretches the overlying epidermis, thinning and eventually ulcerating it. Ulceration was coded as 0, absent; or 1, present. Traumatic ulceration was coded as 0. Mitotic Rate To accept a mitotic figure, hairy extensions of chromatin (condensed chromosomes) had to be unequivocally present, extending from a condensed chromatin mass, and had to correspond to either a metaphase or a telophase figure. 12 The method used to count the TMR was as follows: All hematoxylin and eosin 5 mthick histologic sections of each specimen were evaluated to determine the dermal area of the tumor in which the TMR was greatest. Generally, the TMR was more prevalent at the invading front (usually the deep border) of the tumor. The number of mitoses was counted in a 1-mm 2 area (approximately 5 HPF), beginning in the field with the greatest numbers of mitoses and counting in successive fields, as recommended by the 1982 Pathology Workshop. At the time the study was planned, it was not clear which was the most valid and appropriate method of determining the prognostic significance of the TMR. Therefore, the TMR was first analyzed as a continuous variable without grouping, then by forming two separate groups. Method A The original 1972 Sydney Classification of Malignant Melanoma recommended that TMR be expressed as the average number of mitoses in at least 10 HPF over the entire lesion and that tumors be classified as having Grade I TMR when there was less than one mitosis per five HPFs, Grade II when there were one to four mitoses per five HPF, and Grade III when there were five or more mitoses per five HPF. Although these original groupings were used in the current study, the original method for counting TMR was not employed. Rather, TMR was determined using the recommendations of the 1982 Pathology Workshop. Five HPF were regarded as approximately equivalent to 1 mm 2. Coding using Method A was 1: 0 mitoses/mm 2 ; 2: 1 4 mitoses/mm 2 ;3:5 10 mitoses/mm 2 ; and 4: 11 or more mitoses/mm 2. Note that in the original recommendations, Groups 3 and 4 were combined. Method B According to the 1982 revision of the 1972 Sydney Classification, coding was 1: 0 1 mitoses/mm 2 ;2:2 4 mitoses/mm 2 ; and 3: 5 or more mitoses/mm 2. The grouping 0 1/mm 2 was recommended by the two histopathologists (R.A.S. and G.F.W.) because they considered that identification of the presence or absence of a single mitotic figure would depend on the number of sections (tumor area) of each tumor being evaluated. This varied considerably between cases. Other Putative Prognostic Variables Age was coded in deciles as 1: years; 2: years;...7: years; and 8: 80 years or older. Gender was coded as 0: male; and 1: female. Anatomic site was coded as 0: extremities; and 1: trunk, head and neck. Finally, Clark s level was coded as 2 5. Although details of tumor thickness, ulceration, TMR, age, gender, and anatomic site were known for each of the 3661 patients, a few patients ( 3%) had missing data concerning Clark level of invasion. However, because this study was designed specifically to evaluate the interrelationships among the three former dominant pathologic factors, there was negligible systematic bias due to incomplete data. Statistical Analyses The procedures for statistical analysis used in the current study were the same as those used in the recent study undertaken to validate the proposed revision of the AJCC Melanoma Staging System. 5 These were primarily based on the methods of survival data analysis. Survival times were calculated from the primary mel-

4 Mitotic Rate and Prognosis in Melanoma/Azzola et al FIGURE 1. Survival curves of 2871 patients with localized, cutaneous melanoma stratified by tumor mitoses/mm 2. anoma diagnosis date and considered censored for patients who were alive at the time of last follow-up or who died without evidence of melanoma. Melanomaspecific survival curves were generated according to the Kaplan Meier product-limit method and were compared using the log-rank test. Multivariate analyses of prognostic factors were based on the Cox proportional hazards model and the relative importance of prognostic factors was measured by the chi-square values, based on the Wald test of the coefficient associated with each prognostic factor in the Cox model. RESULTS In the current study, 386 patients had a positive result (uncensored in the Cox analysis), making the ratio of uncensored to total patients Since 1982, the mean follow-up for the uncensored patients has been 4.3 years. Figure 1 demonstrates a decline in the proportion of patients surviving according to a stepwise increase in the number of tumor mitoses/mm 2.Itis interesting to note that patients with tumors recorded as having 0 mitoses/mm 2 had significantly better survival than those with 1 mitosis/mm 2. (P ) However, when the TMR was analyzed as a continuous variable without grouping, no significant differences in survival were observed in the stepwise increases from 1 2/mm 2,2 3/mm 2,3 4/mm 2,or4 5/ mm 2. Mitotic Rate: Method A Figure 2 shows the influence of TMR on the proportion of patients surviving, irrespective of tumor thickness or ulcerative state. There is a highly significant difference in survival between each of the TMR groupings. Figure 3 shows the 10-year survival rates for patients according to tumor thickness and TMR for either nonulcerated (Fig. 3A) or ulcerated (Fig. 3B) tumors. There is a less clearly defined relation among survival rate, tumor thickness, and TMR in ulcerated, thick tumors than in nonulcerated, thinner ones. The Cox regression analysis was performed by including TMR either as a continuous variable without grouping or as a grouped variable. We found that the predictability of the model with TMR included as a grouped variable was far better than that of the model with TMR treated as a continuous variable. The Cox regression analysis for these 3661 patients (Table 1) indicates that TMR was the second most important independent prognostic factor. This is followed by the age of the patient, ulcerative state of the tumor, gender, and to a lesser extent, anatomic site of the primary lesion. Clark level did not reach statistical significance as an independent prognostic factor. Therefore, older patients, patients with ulcerated melanomas, male patients, and patients with melanoma located on the trunk or head and neck had worse prognoses than younger patients, patients with nonulcerated melanomas, female patients, and patients with melanomas located on the extremities, respectively. Mitotic Rate: Method B Figure 4 shows the influence of TMR on the proportion of patients surviving, irrespective of tumor thickness or its ulcerative state. Once again, there is a highly significant difference between each of the TMR groupings. Figure 5 shows the 10-year survival rates for patients according to tumor thickness and TMR in patients with nonulcerated (Fig. 5A) and ulcerated (Fig. 5B) tumors. There is a less clearly defined relation

5 1492 CANCER March 15, 2003 / Volume 97 / Number 6 FIGURE 2. Survival curves of 3661 patients with localized, cutaneous melanoma when tumor mitoses/mm 2 were grouped into four categories (Method A). between tumor thickness and TMR in ulcerated, thick tumors than in nonulcerated, thinner ones. The Cox regression analysis shown in Table 2 indicates that the age of the patient was the second most important independent prognostic factor followed by the ulcerative state of the tumor, TMR, gender, and, to a lesser extent, anatomic site of primary lesion. Clark level did not attain statistical significance as an independent prognostic factor. DISCUSSION The results of the current study have shown that TMR is a powerful independent prognostic factor. If TMR is grouped according to the method recommended by the international committee (Method A), it will be the second most powerful predictor of prognosis (even more predictive than ulceration). If the alternative grouping (Method B) as suggested by our two histopathologists (R.A.S. and G.F.W.) is used, it is still a powerful prognostic predictor but marginally less significant than age of the patient or ulceration. These differing findings may be accounted for by the observation that patients with 0 mitoses/mm 2 fared significantly better that those with 1 mitosis/mm 2 (Fig. 1). Therefore, grouping patients with tumors having 0 mitosis/mm 2 with those having 1 mitosis/mm 2 greatly reduced the significance of TMR as a prognostic variable. This emphasizes the importance of Vollmer s observation 4 that selection (and a clear statement of) groupings is critical. It is noteworthy that the methods used to assess TMR and ulceration in the current study differed slightly from the 1972 recommendations. As we have pointed out earlier, the 1972 consensus suggested that TMR be determined by taking an average number of mitoses over at least 10 HPF without endeavoring to find the area with the highest TMR. In addition, there was a tacit assumption that there was no wide variation in the area of a HPF in the equipment that was used. This has been shown to be incorrect, with TMR expressed as the number of mitoses/10 HPF varying by as much as 600%, depending on the microscope used. 13 The policy of histopathologists from the Department of Anatomical Pathology at the Royal Prince Alfred Hospital is to count the total number of mitoses/mm 2 in the dermal area of the tumor with the highest TMR. This latter method is in accordance with the recommendations of the 1982 Pathology Workshop. We believe that this method is more accurate and scientifically valid and it is particularly useful in the assessment of cases in which only rare (or a single) dermal mitosis is present in the entire specimen. Using the 1972 classification, such cases would defy subgrouping, as the average TMR may be greater than 0 but less than 1 per 10 HPF. Furthermore, this 1982 consensus method is similar to that recommended for the counting of TMR in other solid tumors. 12 With regard to ulceration, traumatic ulceration is often related to the anatomic site or to the architectural configuration of the tumor (i.e., whether it is polypoid or pedunculated) and is generally considered to be prognostically irrelevant unless it is seen in association with another pattern (most commonly attenuative with traumatic). Whether there is a prognostic difference between infiltrative and attenuative ulceration is unknown, although infiltrative ulceration may be a marker of the tumor s infiltrative capacity and the latter a marker of tumor bulk in the dermis. To clarify this uncertainty in prognostic potential, it

6 Mitotic Rate and Prognosis in Melanoma/Azzola et al FIGURE 3. (A) Ten-year survival rates for 2835 patients with nonulcerated, localized, cutaneous melanoma according to tumor thickness and tumor mitoses/ mm 2, the latter being grouped into 4 categories (Method A). (B) Ten-year survival rates for 826 patients with ulcerated, localized, cutaneous melanoma according to tumor thickness and tumor mitoses/mm 2, the latter being grouped into 4 categories (Method A). would be useful for histopathologists to document the ulcerative pattern in their reports. In 1984, attempts were made to document interobserver variation in the classification of various melanoma parameters by specialist melanoma histopathologists in Western Australia. 14 When TMR was assessed by counting the average number of mitoses/ HPF, congruence levels were low (i.e., 66% for lesions with 1 mitosis/5 HPF, 36% for those with 1 5 mitoses/5 HPF, and 57% for those with 5 mitoses/5hpf). The authors concluded that the more objective method of counting TMR as mitoses/mm 2, as recommended by the 1982 Pathology Workshop, should be more reproducible. Therefore, further studies are needed to assess the objectivity and reproducibility in the determination of TMR. Whatever method is used, the counting of TMR relies on the diligence of the assessment by the reporting histopathologist and the number of sections evaluated (particularly if only small numbers of mitoses are present). Despite these TABLE 1 Cox Regression Analysis for 3661 Melanoma Patients with Localized Disease According to Method A a Variable DF Chi-square value (Wald) P value Risk ratio 95% CL Thickness Mitotic rate b Age Ulceration Gender Site Level DF: degree of freedom; CL: confidence limits. a Coding: Thickness was coded as 1: 1.00 mm; 2: mm; 3: mm; and 4: 4.00 mm. Mitotic rate was coded as 1: 0/mm 2 ;2:1 4/mm 2 ;3:5 10/mm 2 ; and 4: 11/mm 2. Age was coded as deciles1:10 19; 2: years;...8: 80 years. Ulceration was coded as 0: absent; and 1: present. Gender was coded as 0: male; and 1: female. Site was coded as 0: extremities; and 1: trunk and head and neck. Level was coded as 2, 3, 4, and 5. b Stratified into four categories: 0, 1 4, 5 10, and 11/mm 2.

7 1494 CANCER March 15, 2003 / Volume 97 / Number 6 FIGURE 4. Survival curves of 3661 patients with localized, cutaneous melanoma when tumor mitoses/mm 2 were grouped into 3 categories (Method B). limitations, our data show that TMR is a powerful prognostic indicator, even in patients with a low TMR. In the Western Australian study, the congruence level for ulceration (without regard to its pattern) was considerably higher than for TMR (i.e., 81% for the presence of ulceration and 96% for its absence). In the current study, Clark level of invasion failed to have significant prognostic impact by multivariate analysis after adjusting for TMR. This is in contrast to the results of the multivariate analysis for the AJCC Melanoma Staging System, 5 in which Clark level emerged as an independent prognostic factor, particularly for melanomas with a thickness of 1.0 mm or less. In the current study, we attempted to replicate the AJCC findings on the prognostic value of Clark level for patients with melanomas of this thickness (n 1259). Patients with Clark Level II melanomas (n 325) were found to have a significantly better survival rate than patients with Level III (n 652) or Level IV (n 276) melanomas, but there was no significant survival difference for patients with Level III or IV melanomas. (The sample size for Level V melanomas [n 4] was too small for an adequate comparison.) The AJCC study had a much larger number of patients (n 5480) with tumor thickness 1.0 mm or less but TMR was not assessed in the AJCC database. We believe it would be useful to include this variable in the AJCC melanoma database for the next revision of the AJCC Melanoma Staging System. A previous attempt to use SMU data to delineate the prognostic significance of various histologic factors did not demonstrate that TMR was an independent prognostic factor. 15 A close correlation was found between TMR and tumor thickness. However, when attempts were made to compensate for this correlation, no clear effect of TMR could be discerned, particularly for thin lesions. Several reasons could account for this previous failure to demonstrate an independent significance of TMR. First, TMR was assessed according to the 1972 recommendations, i.e., recording the average number of mitoses per 10 HPF over the entire lesion. Second, only 694 patients were available for analysis, resulting in some groups being too small to provide meaningful prognostic information. Third, no attempt was made to eliminate referral bias. Fourth, 5-year, not 10-year, survival rates were used as end points. Finally, multivariate statistical analysis using the Cox proportional hazards model was not employed. In a number of other studies, TMR has also failed to emerge as a useful prognostic variable. However, the majority of these studies have also had serious methodologic deficiencies and their conclusions therefore must be interpreted with similar caution. In 1989, Vollmer 4 was the first to attempt to explain in detail the differing conclusions gleaned from these analyses. He extracted from the literature 54 multivariate studies reported in 48 articles from 18 centers. He summarized the results of 31 multivariate studies that included TMR. Fourteen of these showed that TMR did have some prognostic significance, the remainder failing to assign prognostic significance to TMR. Vollmer considered that, in general, the composition of a dataset was the most important factor to be considered when assessing the validity of a study. He suggested that knowledge of which patients were deleted was critical because these deletions could produce biases, some subtle, some major. Such deletions are usually due to a simple lack of data and great caution in the interpretation of results is required if

8 Mitotic Rate and Prognosis in Melanoma/Azzola et al FIGURE 5. (A) Ten-year survival rates for 2835 patients with nonulcerated, localized, cutaneous melanoma according to tumor thickness and tumor mitoses/ mm 2, the latter being grouped into 3 categories (Method B). (B) Ten-year survival rates for 826 patients with ulcerated, localized, cutaneous melanoma according to tumor thickness and tumor mitoses/mm 2, the latter being grouped into 3 categories (Method B). more than 10% of patients are excluded. Referral patterns can also produce bias, so that prognostic conclusions may relate either to melanoma patients in general or to patients with more complex problems who reach a specialized clinic. Although Vollmer drew attention to these critical issues, few subsequent studies have attempted to address them. A more detailed consideration of Vollmer s analysis is instructive. He noted that the 54 studies used 12 different end points of interest, which could be separated into two major categories: binary or time-related categories. Binary events have only two possible outcomes (i.e., the patient did or did not develop a recurrence or alternatively did or did not die of melanoma). A time-related end point is time to failure, expressed as a numeric value (weeks, months, or years) whether it be a local, lymph nodal, or distant recurrence, or ultimately, death. All these end points require long term follow-up to be of any practical value. Because at TABLE 2 Cox Regression Analysis for 3661 Melanoma Patients with Localized Disease According to Method B a Variable DF Chi-square value (Wald) P value Risk ratio 95% CL Thickness Age Ulceration Mitotic rate b Gender Site Level DF: degree of freedom; CL: confidence limits. a Coding: Thickness was coded as 1: 1.00 mm; 2: mm; 3: mm; and 4: 4.00 mm. Mitotic rate was coded as 1: 0 1/mm 2 ;2:2 4/mm 2 ; and 3: 5mm 2. Age was coded as deciles 1: 10 19; 2: 20 29,...8, 80 years. Ulceration was coded as 0: absent; and 1: present. Gender was coded as 0: male; and 1: female. Site was coded as 0: extremities; and 1: trunk and head and neck. Level was coded as 2, 3, 4, and 5. b Stratified into three categories: 0 1, 2 4, 5/mm 2.

9 1496 CANCER March 15, 2003 / Volume 97 / Number 6 TABLE 3 Summary of Recent Multivariate Studies on Mitosis Studies No. of patients Mean follow-up (yrs) Factors studied TMR cutoff End point Significance of TMR Vossaert et al , 1, 2, 3/mm 2 10-yr survival MacKie et al , 1 5, 5/10HPF 5-yr survival Barnhill et al , 0.1 6, 6/mm 2 5-yr survival Ostmeier et al (median) 16 3, 3/mm 2 First recurrence Wagner et al , 3 5, 5/HPF SNB status Massi et al , 0.1 6, 6/mm 2, 10, 10/mm 2 10-yr survival Schmidt-Wendtner et al PI, mod PI 10-yr survival TMR: tumor mitotic rate; HPF: high power field; SNB: sentinel lymph node biopsy; PI: prognostic index (tumor thickness TMR); modified PI: tumor thickness 2 TMR. least 60% of patients who present with Stage I and II melanoma survive for more than 10 years, studies should ideally be long term and large enough to define accurately the required end point of interest. However, most of the 54 studies reviewed by Vollmer were neither long term nor large. For example, a follow-up interval was reported for only 30 of the 54 studies. For those studies in which it was reported, the mean was about 5 years. The number of patients studied ranged from an unacceptably low number of 44 to 3445 (average 529). The majority of studies (i.e., 47 of 54 studies) used Cox proportional hazards survival analysis. The remainder used logistic regression or multivariate discrimination analyses. Only 21 of the 54 studies reported the number of uncensored patients (patients with a positive result) and the proportion of uncensored to total patients ranged from a low of 3% to 66%. The number of factors incorporated into the Cox analysis ranged from 4 to 25 and often key factors such as ulceration and particularly TMR were omitted, the latter being analyzed in only 31 of the 54 studies. Most important, the method of coding for the analyses was not specified or was only suggested in 52 of the 54 studies and the tumor thickness break points used were inconsistent. Vollmer considered that the selection of break points for an otherwise continuous variable was artificial and arbitrary and he favored a continuous function of thickness. With regard to TMR, some studies used a prognostic index (PI) in their analyses, defined as tumor thickness multiplied by TMR. This, therefore, becomes a continuous function of thickness. It is a second-order factor and because TMR is related to tumor thickness, it is nearly like multiplying tumor thickness by itself. It is noteworthy that Vollmer suggested that TMR might need further study using standardized methods of coding and reporting such as the number of mitoses/mm 2. Even simple binary factors such as ulceration were coded differently in the studies reviewed. Sometimes they were recorded as present or absent, but were coded by others as or 3 mm in greatest dimension. Similarly, the anatomic site of the primary lesion was recorded variously as extremity versus axial (i.e., as a binary factor) or as head and neck versus trunk versus extremity versus acral (i.e., as a four-level factor). Vollmer considered that the age of the patient should probably be regarded as a continuous parameter and suggested that any subdivision would be arbitrary. Since Vollmer s seminal review of this subject was published in 1989, several other studies have attempted to assess the prognostic importance of TMR (Table 3). Six of the seven analyses attached biologic importance and prognostic significance to TMR. Unfortunately, however, some of these studies failed to avoid all the pitfalls previously highlighted by Vollmer, making it difficult to draw firm conclusions from them. In its initial analysis of intermediate thickness melanomas ( mm) in 1987, the New York University Melanoma Cooperative Group 23 found that TMR had no prognostic significance although ulceration achieved independent significance (P 0.015). However, when a PI was derived (which was the product of tumor thickness and TMR), a significant cutoff was achieved at PI less than 19 versus PI greater than or equal to 19. This group concluded that significant predictability should be contributed to Breslow thickness by multiplying it by TMR and suggested that mitoses/mm 2 may be a correlate of the rate of growth of a subgroup of melanoma cases which in turn is related directly to the metastatic potential of melanoma. In a later New York University analysis by Vossaert et al. 16 (Table 3), which included 832 melanomas of all thicknesses, TMR itself again failed to reach prognostic significance although ulceration strengthened its significance (P ). The results of the population-based Scottish Melanoma Group study 17 (Table 3) indicated that TMR, considered in isolation (i.e., in a univariate analysis),

10 Mitotic Rate and Prognosis in Melanoma/Azzola et al was the third most important prognostic factor after ulceration and tumor thickness. However, when corrected for ulceration, TMR fell to seventh place (behind gender, anatomic site, Clark level, and age). Therefore, the authors stressed the folly of considering features of putative prognostic significance in isolation, i.e., by univariate analysis. Surprisingly, they found ulceration to be a far more significant independent factor than tumor thickness (chi-square test 188 vs. 52, respectively) in their relatively small (n 289) study. This, together with their poor 5-year survival rate (30% less than that reported by Soong et al. 24 ) led them to conclude that there may be geographic variations in prognostic factors due, for example, to extremes in ultraviolet radiation. This suggested that there might be a need for each center to derive its own model. Barnhill et al. 18 (Table 3) conducted the first comprehensive population-based (Connecticut Tumor Registry) analysis of prognostic factors in the U.S. They evaluated the significance of TMR in 548 patients using the cutoff points proposed by Clark et al. 25 These were 0, 0.1 6, and 6 mitoses/mm 2. They found that only two variables (tumor thickness and TMR) had independent effects. Ulceration of the lesion failed to reach significance as a prognostic indicator, as did age, gender, and anatomic site. Their reasons for these discrepancies between multifactorial analyses were similar to those proposed by Vollmer. However, they added that for histologic parameters, interobserver variation due to subjectivity may be just as important, with perhaps some effect of geographic variability. They concluded that more objective methods of assessing proliferation may provide better indications of prognosis. A German study of 691 patients by Ostmeier et al. 19 (Table 3) found that ulceration no longer demonstrated independent significance when TMR was included in their prognostic model. They cited reasons similar to those proposed by Barnhill et al. 18 for conflicting results from multivariate analyses. Using a different approach to assess the prognostic significance of TMR, Wagner et al. 20 (Table 3), from the Indiana University Interdisciplinary Melanoma Program, tested the ability of this parameter to predict lymph node positivity after sentinel lymph node biopsy in 279 patients. They found that TMR and ulceration achieved similar levels of prognostic significance (P 0.04 and P 0.03, respectively). On the basis of these results, they suggested performance of sentinel lymph node biopsy where ulceration is present and TMR is high, irrespective of tumor thickness. However, a major concern about this study is that the TMR groupings used were extraordinarily high (i.e., low: 3 mitoses/hpf; intermediate: 3 5 mitoses/hpf; and high: 5 mitoses/hpf). These groupings approximately correspond to less than 15 mitoses/mm 2, mitoses/mm 2, and greater than 25 mitoses/ mm 2. In their small study of 140 patients with thick tumors ( 3 mm) from Florence, Massi et al. 21 (Table 3) found that the cutoff point of 10 mitoses/mm 2 versus 10 mitoses/mm 2 proved to be significantly predictive of 10-year survival rates, with rates of 56% and 24%, respectively (P ). Ulcerative state also was found to be significantly predictive but less so (60% 10-year survival for patients with nonulcerated lesions vs. 40% for those with ulcerated lesions; P 0.006). They also concluded that TMR, as a continuous variable, acts as an independent risk factor. For practical purposes, the categorization of continuous prognostic factors (e.g., tumor thickness and TMR) is always needed. Their explanations for the differences in prognostic significance of TMR cited in the literature included variations in recording this feature (particularly the scoring system used), the number of fields evaluated, and the quality of the histologic material available for analysis. In what to our knowledge is the largest study published to date, from the University of Munich by Schmidt-Wendtner et al. 22 (Table 3), TMR was specifically analyzed both as a PI and a modified PI, the latter being the product of the tumor thickness squared and the number of mitoses/mm 2. In their 2715 patient series, they found modified PI to be a slightly more accurate determinant of prognosis than the PI as proposed by Schmoeckel and Braun-Falco. 26 The authors stated that using the square of tumor thickness (which approximately represents the surface of the tumor) may result in greater prognostic predictability. In our view, such an assumption most likely is incorrect because it does not reflect our experience in reviewing the histopathology of large numbers of primary melanomas. A major deficiency in this study is that ulceration was not documented from the beginning and, therefore, was not part of their analysis. No account was taken of the probable interrelation among tumor thickness, TMR, and ulceration. Some centers attributed importance to PI. Nevertheless, the critical values derived for PI vary considerably among centers. For example, values ranged from less than 12 versus 12 in the Schmoeckel and Braun-Falco study, 26 to 19 versus 19 in the New York University Melanoma Cooperative Group study. 23 In the current study, we attempted to minimize the pitfalls inherent in multifactorial analyses so that the informed reader may assess the validity of our findings on the prognostic significance of TMR in a primary cutaneous melanoma. Less than 3% of SMU

11 1498 CANCER March 15, 2003 / Volume 97 / Number 6 patients were excluded because variables germaine to this analysis were missing. Any referral bias was minimized by selecting only patients treated from the outset at the SMU, although we cannot infer from this that the final study dataset was truly population based. Large numbers of patients were studied with sufficient follow-up for an adequate proportion of them to provide valid estimates of survival. The number of uncensored patients was high and coding for all key prognostic factors was stipulated clearly. Using these rigorous methods to study TMR and its complex interrelationships with tumor thickness and ulceration, a powerful and clear-cut prognostic significance of TMR was found. We believe that this is the largest and most comprehensive study of its kind published to date. Therefore, this finding has important practical implications. If confirmed by similarly vigorous studies from other centers, it should allow more accurate prognostic information to be determined for individual patients with primary melanomas and more precise stratification of groups of patients entering clinical trials of adjuvant therapy. REFERENCES 1. Walker SH, Duncan DB. Estimation of the probability of an event as a function of several independent variables. Biometrika. 1967;54: Cox DR. The analysis of binary data. London: Chapman and Hall, Cox DR. Regression model and life tables (with discussion). J Stat Soc [B]. 1972;34: Vollmer RT. Malignant melanoma. A multivariate analysis of prognostic factors. Pathol Annu. 1989;24: Balch CM, Soong S-J, Gershenwald JE, et al. Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer Melanoma Staging System. J Clin Oncol. 2001;19: Balch CM, Buzaid AC, Soong S-J, et al. Final version of the American Joint Committee on Cancer Staging System for Cutaneous Melanoma. J Clin Oncol. 2001;19: McGovern VJ, Cochran AJ, Van Der Esch EP, Little JH, MacLennan R. The classification of malignant melanoma, its histological reporting and registration: a revision of the 1972 classification. Pathology. 1986;18: McGovern VJ, Mihm MC, Bailly C, et al. The classification of malignant melanoma and its histologic reporting. Cancer. 1973;32: Breslow A. Thickness, cross sectional areas and depth of invasion in the prognosis of cutaneous melanoma. Ann Surg. 1970;172: Thompkins VN. Cutaneous melanoma: ulceration as a poor prognostic sign. Cancer. 1953; 6: Petersen NC, Bodenham DC, Lloyd OC. Malignant melanoma of the skin: a study of the origin, development, aetiology, spread, treatment and prognosis. Br J Plast Surg. 1962;15: Hilsenbeck S, Allred D. Improved methods of estimating mitotic figures in solid tumours. Hum Pathol. 1990;21: Ellis PSJ, Whitehead R. Mitotis counting a need for reappraisal. Hum Pathol. 1981;12: Heenan PJ, Matz LR, Blackwell JB, et al. Inter-observer variation between pathologists in the classification of cutaneous malignant melanoma in Western Australia. Histopathology. 1984;8: McGovern VJ, Shaw HM, Milton GW, Farago GA. Prognostic significance of the histological features of malignant melanoma. Histopathology. 1979;3: Vossaert KA, Silverman MK, Kopf AW, et al. Influence of gender on survival in patients with stage I malignant melanoma. J Am Acad Dermatol. 1992;26: MacKie RM, Aitchison T, Sirel JM, McLaren K, Watt DC. Prognostic models for subgroups of melanoma patients from the Scottish Melanoma Group database , and their subsequent validation. Br J Cancer. 1995;71: Barnhill RL, Fine JA, Roush GC, Berwick M. Predicting fiveyear outcome for patients with cutaneous melanoma in a population-based study. Cancer. 1996;78: Ostmeier H, Fuchs B, Otto F, et al. Can immunohistochemical markers and mitotic rate improve prognostic precision in patients with primary melanoma? Cancer. 1999;85: Wagner JD, Gordon MS, Chuang T-Y, et al. Predicting sentinel and residual lymph node basin disease after sentinel lymph node biopsy for melanoma. Cancer. 2000;89: Massi D, Borgognoni L, Franchi A, Martini L, Reali UM, Santucci M. Thick cutaneous malignant melanoma: a reappraisal of prognostic factors. Melanoma Res. 2000;10: Schmidt-Wendtner MH, Baumert J, Schmidt M, Plewig G, Volkenandt M, Holzel D. Prognostic index for cutaneous melanoma: an analysis after follow-up of 2715 patients. Melanoma Res. 2001;11: Kopf AW, Gross DF, Rogers GS, et al. Prognostic index for malignant melanoma. Cancer. 1987;59: Soong S-J, Shaw HM, Balch CM, McCarthy WH, Urist MM, Lee JY. Predicting recurrence and survival in localized melanoma: a multivariate approach. World J Surg. 1992;16: Clark WH, Elder DE, DuPont G, et al. Model predicting survival in stage I melanoma based on tumor progression. J Natl Cancer Inst. 1989;81: Schmoeckel C, Braun-Falco O. Prognostic index in malignant melanoma. Arch Dermatol. 1978;114:

Citation for published version (APA): Francken, A. B. (2007). Primary and metastatic melanoma: aspects of follow-up and staging s.n.

Citation for published version (APA): Francken, A. B. (2007). Primary and metastatic melanoma: aspects of follow-up and staging s.n. University of Groningen Primary and metastatic melanoma Francken, Anne Brecht IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check

More information

Polypoid Melanoma, A Virulent Variant of the Nodular Growth Pattern

Polypoid Melanoma, A Virulent Variant of the Nodular Growth Pattern Polypoid Melanoma, A Virulent Variant of the Nodular Growth Pattern ELIZABETH A. MANCI, M.D., CHARLES M. BALCH, M.D..TARIQ M. MURAD, M.D., PH.D., AND SENG/JAW SOONG, PH.D. Manci, Elizabeth A., Balch, Charles

More information

Tumor Mitotic Rate Added to the Equation: Melanoma Prognostic Factors Changed?

Tumor Mitotic Rate Added to the Equation: Melanoma Prognostic Factors Changed? Ann Surg Oncol (2015) 22:2978 2987 DOI 10.1245/s10434-014-4349-3 ORIGINAL ARTICLE MELANOMAS Tumor Mitotic Rate Added to the Equation: Melanoma Prognostic Factors Changed? A Single-Institution Database

More information

Malignant Melanoma in Turkey: A Single Institution s Experience on 475 Cases

Malignant Melanoma in Turkey: A Single Institution s Experience on 475 Cases Malignant Melanoma in Turkey: A Single Institution s Experience on 475 Cases Faruk Tas, Sidika Kurul, Hakan Camlica and Erkan Topuz Institute of Oncology, Istanbul University, Istanbul, Turkey Received

More information

Patient age and cutaneous malignant melanoma: Elderly patients are likely to have more aggressive histological features and poorer survival

Patient age and cutaneous malignant melanoma: Elderly patients are likely to have more aggressive histological features and poorer survival MOLECULAR AND CLINICAL ONCOLOGY 7: 1083-1088, 2017 Patient age and cutaneous malignant melanoma: Elderly patients are likely to have more aggressive histological features and poorer survival FARUK TAS

More information

Thin Melanoma. N Context. The incidence of malignant melanoma is

Thin Melanoma. N Context. The incidence of malignant melanoma is Thin Melanoma David E. Elder, MB ChB, FRCPA N Context. The incidence of malignant melanoma is increasing and a preponderance of the melanomas diagnosed today are thin in terms of Breslow criteria. Although

More information

Johan Lyth, J Hansson, C Ingvar, E Mansson-Brahme, P Naredi, U Stierner, G Wagenius and C Lindholm. Linköping University Post Print

Johan Lyth, J Hansson, C Ingvar, E Mansson-Brahme, P Naredi, U Stierner, G Wagenius and C Lindholm. Linköping University Post Print Prognostic subclassifications of T1 cutaneous melanomas based on ulceration, tumour thickness and Clark s level of invasion: results of a population-based study from the Swedish Melanoma Register Johan

More information

ORIGINAL ARTICLE. Clinical Node-Negative Thick Melanoma

ORIGINAL ARTICLE. Clinical Node-Negative Thick Melanoma ORIGINAL ARTICLE Clinical Node-Negative Thick Melanoma George I. Salti, MD; Ashwin Kansagra, MD; Michael A. Warso, MD; Salve G. Ronan, MD ; Tapas K. Das Gupta, MD, PhD, DSc Background: Patients with T4

More information

Talk to Your Doctor. Fact Sheet

Talk to Your Doctor. Fact Sheet Talk to Your Doctor Hearing the words you have skin cancer is overwhelming and would leave anyone with a lot of questions. If you have been diagnosed with Stage I or II cutaneous melanoma with no apparent

More information

Sentinel Node Alphabet Soup: MSLT-1, DeCOG-SLT, MSLT-2, UNC

Sentinel Node Alphabet Soup: MSLT-1, DeCOG-SLT, MSLT-2, UNC Sentinel Node Alphabet Soup: MSLT-1, DeCOG-SLT, MSLT-2, UNC David W. Ollila MD James and Jesse Millis Professor of Surgery University of North Carolina, Chapel Hill Disclosures: None July 15, 2018 AJCC

More information

Melanoma-Back to Basics I Thought I Knew Ya! Paul K. Shitabata, M.D. Dermatopathologist APMG

Melanoma-Back to Basics I Thought I Knew Ya! Paul K. Shitabata, M.D. Dermatopathologist APMG Melanoma-Back to Basics I Thought I Knew Ya! Paul K. Shitabata, M.D. Dermatopathologist APMG At tumor board, a surgeon insists that all level II melanomas are invasive since they have broken through the

More information

Rebecca Vogel, PGY-4 March 5, 2012

Rebecca Vogel, PGY-4 March 5, 2012 Rebecca Vogel, PGY-4 March 5, 2012 Historical Perspective Changes In The Staging System Studies That Started The Talk Where We Go From Here Cutaneous melanoma has become an increasingly growing problem,

More information

Melanoma Update: 8th Edition of AJCC Staging System

Melanoma Update: 8th Edition of AJCC Staging System Melanoma Update: 8th Edition of AJCC Staging System Rosalie Elenitsas, M.D. Professor of Dermatology Director, Dermatopathology University of Pennsylvania DISCLOSURE OF RELATIONSHIPS WITH INDUSTRY None

More information

ORIGINAL ARTICLE PROGNOSTIC IMPLICATION OF SENTINEL LYMPH NODE BIOPSY IN CUTANEOUS HEAD AND NECK MELANOMA

ORIGINAL ARTICLE PROGNOSTIC IMPLICATION OF SENTINEL LYMPH NODE BIOPSY IN CUTANEOUS HEAD AND NECK MELANOMA ORIGINAL ARTICLE PROGNOSTIC IMPLICATION OF SENTINEL LYMPH NODE BIOPSY IN CUTANEOUS HEAD AND NECK MELANOMA Benjamin E. Saltman, MD, 1 Ian Ganly, MD, 2 Snehal G. Patel, MD, 2 Daniel G. Coit, MD, 3 Mary Sue

More information

Malignant tumors of melanocytes : Part 3. Deba P Sarma, MD., Omaha

Malignant tumors of melanocytes : Part 3. Deba P Sarma, MD., Omaha Malignant tumors of melanocytes : Part 3 Deba P Sarma, MD., Omaha Let s go over one case of melanoma using the following worksheet. Of the various essential information that needs to be included in the

More information

Updates on Melanoma: Are You Following the Latest Guidelines of Care? Jerry Brewer, MD

Updates on Melanoma: Are You Following the Latest Guidelines of Care? Jerry Brewer, MD Updates on Melanoma: Are You Following the Latest Guidelines of Care? Jerry Brewer, MD Disclosure Statement Update on Melanoma Are You Following the Latest Guidelines of Care? I, Jerry D. Brewer, MD, do

More information

Recently, serum tumor marker CYFRA 21-1 has shown a high

Recently, serum tumor marker CYFRA 21-1 has shown a high 670 CORRESPONDENCE Serum CYFRA 21-1 Is One of the Most Reliable Tumor Markers for Breast Carcinoma Recently, serum tumor marker CYFRA 21-1 has shown a high sensitivity and specificity in patients with

More information

FORUM. Collaboration between clinicians and pathologists: a necessity for the optimal management of melanoma patients

FORUM. Collaboration between clinicians and pathologists: a necessity for the optimal management of melanoma patients Collaboration between clinicians and pathologists: a necessity for the optimal management of melanoma patients Richard Scolyer, 1,2 John Thompson, 1,3 Jonathan Stretch, 1,3 Stanley McCarthy 1,2 1 Sydney

More information

Update on 8 th Edition Cutaneous AJCC Staging of Primary Cutaneous Melanoma. Michael T. Tetzlaff MD, PhD

Update on 8 th Edition Cutaneous AJCC Staging of Primary Cutaneous Melanoma. Michael T. Tetzlaff MD, PhD Update on 8 th Edition Cutaneous AJCC Staging of Primary Cutaneous Melanoma Michael T. Tetzlaff MD, PhD Associate Professor Departments of Pathology (Dermatopathology) and Translational and Molecular Pathology

More information

Desmoplastic Melanoma: Surgical Management and Adjuvant Therapy

Desmoplastic Melanoma: Surgical Management and Adjuvant Therapy Desmoplastic Melanoma: Surgical Management and Adjuvant Therapy Dale Han, MD Assistant Professor Department of Surgery Section of Surgical Oncology No disclosures Background Desmoplastic melanoma (DM)

More information

Increasing Age Is Associated with Worse Prognostic Factors and Increased Distant Recurrences despite Fewer Sentinel Lymph Node Positives in Melanoma

Increasing Age Is Associated with Worse Prognostic Factors and Increased Distant Recurrences despite Fewer Sentinel Lymph Node Positives in Melanoma Increasing Age Is Associated with Worse Prognostic Factors and Increased Distant Recurrences despite Fewer Sentinel Lymph Node Positives in Melanoma A. J. Page, Emory University A. Li, Emory University

More information

Primary Cutaneous Melanoma Pathology Reporting Proforma DD MM YYYY. *Tumour site. *Specimen laterality. *Specimen type

Primary Cutaneous Melanoma Pathology Reporting Proforma DD MM YYYY. *Tumour site. *Specimen laterality. *Specimen type Primary Cutaneous Melanoma Pathology Reporting Proforma Includes the International Collaboration on Cancer reporting dataset denoted by * Family name Given name(s) Date of birth DD MM YYYY Sex Male Female

More information

1 Cancer Council Queensland, Brisbane, Queensland, Australia.

1 Cancer Council Queensland, Brisbane, Queensland, Australia. Title: Diagnosis of an additional in situ does not influence survival for patients with a single invasive : A registry-based follow-up study Authors: Danny R Youlden1, Kiarash Khosrotehrani2, Adele C Green3,4,

More information

Impact of Prognostic Factors

Impact of Prognostic Factors Melanoma Prognostic Factors: where we started, where are we going? Impact of Prognostic Factors Staging Management Surgical intervention Adjuvant treatment Suraj Venna, MD Assistant Clinical Professor,

More information

Disclosures. SLNB for Melanoma 25/02/2014 SENTINEL LYMPH NODE BIOPSY FOR MELANOMA: CURRENT GUIDELINES AND THEIR CLINICAL APPLICATION

Disclosures. SLNB for Melanoma 25/02/2014 SENTINEL LYMPH NODE BIOPSY FOR MELANOMA: CURRENT GUIDELINES AND THEIR CLINICAL APPLICATION 8 th Canadian Melanoma Conference February 22, 2014 Rimrock Resort Hotel, Banff, Alberta SENTINEL LYMPH NODE BIOPSY FOR MELANOMA: CURRENT GUIDELINES AND THEIR CLINICAL APPLICATION Christopher Bichakjian,

More information

Quality ID #397: Melanoma Reporting National Quality Strategy Domain: Communication and Care Coordination

Quality ID #397: Melanoma Reporting National Quality Strategy Domain: Communication and Care Coordination Quality ID #397: Melanoma Reporting National Quality Strategy Domain: Communication and Care Coordination 2018 OPTIONS FOR INDIVIDUAL MEASURES: CLAIMS ONLY MEASURE TYPE: Outcome DESCRIPTION: Pathology

More information

Prognostic Importance of the Mitotic Marker Phosphohistone H3 in Cutaneous Nodular Melanoma

Prognostic Importance of the Mitotic Marker Phosphohistone H3 in Cutaneous Nodular Melanoma ORIGINAL ARTICLE Prognostic Importance of the Mitotic Marker Phosphohistone H3 in Cutaneous Nodular Melanoma Rita G. Ladstein 1, Ingeborg M. Bachmann 1,2, Oddbjørn Straume 1 and Lars A. Akslen 1,3 Mitotic

More information

Melanoma Underwriting Presented at 2018 AHOU Conference. Hank George FALU

Melanoma Underwriting Presented at 2018 AHOU Conference. Hank George FALU Melanoma Underwriting Presented at 2018 AHOU Conference Hank George FALU MELANOMA EPIDEMIOLOGY 70-80,000 American cases annually Majority are in situ or thin > 20% are diagnosed age 45 8-9,000 melanoma

More information

Desmoplastic Melanoma: Clinical Behavior and Management Implications

Desmoplastic Melanoma: Clinical Behavior and Management Implications Desmoplastic Melanoma: Clinical Behavior and Management Implications Collier S. Pace, MD, a Jyoti P. Kapil, MD, b Luke G. Wolfe, MS, c Brian J. Kaplan, MD, c and James P. Neifeld, MD c a Division of Plastic

More information

Michael T. Tetzlaff MD, PhD

Michael T. Tetzlaff MD, PhD American Joint Cancer Committee (AJCC) staging system for primary cutaneous melanoma (8 th Edition) and principles of sentinel lymph node evaluation Emphasis on concise and accurate reporting of primary

More information

WHAT DOES THE PATHOLOGY REPORT MEAN?

WHAT DOES THE PATHOLOGY REPORT MEAN? Melanoma WHAT IS MELANOMA? Melanoma is a type of cancer that affects cells called melanocytes. These cells are found mainly in skin but also in the lining of other areas such as nose and rectum, and also

More information

Is There a Benefit to Sentinel Lymph Node Biopsy in Patients With T4 Melanoma?

Is There a Benefit to Sentinel Lymph Node Biopsy in Patients With T4 Melanoma? Is There a Benefit to Sentinel Lymph Node Biopsy in atients With T4 Melanoma? Csaba Gajdos, MD 1 ; Kent A. Griffith, MH, MS 2 ; Sandra L. Wong, MD 1 ; Timothy M. Johnson, MD 1,3 ; Alfred E. Chang, MD 1

More information

Skin lesions suspicious for melanoma: New Zealand excision margin guidelines in practice

Skin lesions suspicious for melanoma: New Zealand excision margin guidelines in practice Skin lesions suspicious for melanoma: excision margin guidelines in practice Tess Brian MBBS; 1 Michael B. Jameson MBChB, FRACP, FRCP, PhD 2,3 1 Department of Plastic and Reconstructive Surgery, Waikato

More information

Surgical Issues in Melanoma

Surgical Issues in Melanoma Surgical Issues in Melanoma Mark B. Faries, MD, FACS Director, Donald L. Morton Melanoma Research Program Director, Surgical Oncology Training Program Professor of Surgery John Wayne Cancer Institute Surgical

More information

Prognostic value of tumour thickness in cutaneous malignant melanoma

Prognostic value of tumour thickness in cutaneous malignant melanoma J Clin Pathol 1983;36:51-56 Prognostic value of tumour thickness in cutaneous malignant melanoma IONA JEFFREY, PATRICK ROYSTON, CHRISTOPHER SOWTER, GERARD SLAVIN, ASHLEY PRICE, ARIELA POMERANCE,* SALEEM

More information

Measure #397: Melanoma Reporting National Quality Strategy Domain: Communication and Care Coordination

Measure #397: Melanoma Reporting National Quality Strategy Domain: Communication and Care Coordination Measure #397: Melanoma Reporting National Quality Strategy Domain: Communication and Care Coordination 2017 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY MEASURE TYPE: Outcome DESCRIPTION: Pathology reports

More information

Peritoneal Involvement in Stage II Colon Cancer

Peritoneal Involvement in Stage II Colon Cancer Anatomic Pathology / PERITONEAL INVOLVEMENT IN STAGE II COLON CANCER Peritoneal Involvement in Stage II Colon Cancer A.M. Lennon, MB, MRCPI, H.E. Mulcahy, MD, MRCPI, J.M.P. Hyland, MCh, FRCS, FRCSI, C.

More information

Protocol applies to melanoma of cutaneous surfaces only.

Protocol applies to melanoma of cutaneous surfaces only. Melanoma of the Skin Protocol applies to melanoma of cutaneous surfaces only. Procedures Biopsy (No Accompanying Checklist) Excision Re-excision Protocol revision date: January 2005 Based on AJCC/UICC

More information

Breslow Thickness and Clark Level Evaluation in Albanian Cutaneous Melanoma

Breslow Thickness and Clark Level Evaluation in Albanian Cutaneous Melanoma Research DOI: 10.6003/jtad.16104a2 Breslow Thickness and Clark Level Evaluation in Albanian Cutaneous Melanoma Daniela Xhemalaj, MD, Mehdi Alimehmeti, MD, Susan Oupadia, MD, Majlinda Ikonomi, MD, Leart

More information

Nodal Treatment in Melanoma: Snow to MSLT-II

Nodal Treatment in Melanoma: Snow to MSLT-II Nodal Treatment in Melanoma: Snow to MSLT-II Mark B. Faries, MD, FACS Director, Donald L. Morton Melanoma Research Program Program Director, JWCI Complex General Surgical Oncology Fellowship Director,

More information

Therapeutic Lymph Node Dissection in Melanoma: Different Prognosis for Different Macrometastasis Sites?

Therapeutic Lymph Node Dissection in Melanoma: Different Prognosis for Different Macrometastasis Sites? Ann Surg Oncol (01) 19:91 91 DOI.14/s44-01-401- ORIGINAL ARTICLE MELANOMAS Therapeutic Lymph Node Dissection in Melanoma: Different Prognosis for Different Macrometastasis Sites? K. P. Wevers, MD, E. Bastiaannet,

More information

Molecular Enhancement of Sentinel Node Evaluation

Molecular Enhancement of Sentinel Node Evaluation Cochran Illustrations 060104 Molecular Enhancement of Sentinel Node Evaluation Alistair Cochran, MD and Rong Huang MD Departments of Pathology and Laboratory Medicine and Surgery, David Geffen School of

More information

Patients with thick cutaneous melanoma ( 4 mm) pose a challenge. Prognostic Factors in Patients with Thick Cutaneous Melanoma (> 4 mm)

Patients with thick cutaneous melanoma ( 4 mm) pose a challenge. Prognostic Factors in Patients with Thick Cutaneous Melanoma (> 4 mm) 1049 Prognostic Factors in Patients with Thick Cutaneous Melanoma (> 4 mm) Elizabeth Zettersten, M.D. 1 Richard W. Sagebiel, M.D. 1 James R. Miller III, Ph.D. 1,2 Sreedhar Tallapureddy, M.D. 1 Stanley

More information

6/22/2015. Original Paradigm. Correlating Histology and Molecular Findings in Melanocytic Neoplasms

6/22/2015. Original Paradigm. Correlating Histology and Molecular Findings in Melanocytic Neoplasms 6 Correlating Histology and Molecular Findings in Melanocytic Neoplasms Pedram Gerami MD, Associate Professor of Dermatology and Pediatrics at Northwestern University Disclosures: I have been a consultant

More information

Katsuhiro Yamada, Natsuko Noguti, Masaaki Tsuda, Hazime Nagato, Naoko Hasunuma, Yoshihiro Umebayashi and Motomu Manabe

Katsuhiro Yamada, Natsuko Noguti, Masaaki Tsuda, Hazime Nagato, Naoko Hasunuma, Yoshihiro Umebayashi and Motomu Manabe Akita J Med 36 : 45-52, 2009 45 Katsuhiro Yamada, Natsuko Noguti, Masaaki Tsuda, Hazime Nagato, Naoko Hasunuma, Yoshihiro Umebayashi and Motomu Manabe (Received 22 December 2008, Accepted 15 January 2009)

More information

Morphologic characteristics of nevi associated with melanoma: a clinical, dermatoscopic and histopathologic analysis

Morphologic characteristics of nevi associated with melanoma: a clinical, dermatoscopic and histopathologic analysis DERMATOLOGY PRACTICAL & CONCEPTUAL www.derm101.com Morphologic characteristics of nevi associated with melanoma: a clinical, dermatoscopic and histopathologic analysis Temeida Alendar 1, Harald Kittler

More information

Controversies and Questions in the Surgical Treatment of Melanoma

Controversies and Questions in the Surgical Treatment of Melanoma Controversies and Questions in the Surgical Treatment of Melanoma Giorgos C. Karakousis, M.D. Assistant Professor of Surgery Division of Endocrine and Oncologic Surgery University of Pennsylvania School

More information

What are the new AJCC Staging System changes, and how will they affect my patients?

What are the new AJCC Staging System changes, and how will they affect my patients? What are the new AJCC Staging System changes, and how will they affect my patients? Emily Y. Chu, M.D., Ph.D. Assistant Professor of Dermatology & Pathology and Laboratory Medicine University of Pennsylvania

More information

Melanoma of the Skin INTRODUCTION SUMMARY OF CHANGES

Melanoma of the Skin INTRODUCTION SUMMARY OF CHANGES 24 Melanoma of the Skin C44.0 Skin of lip, NOS C44.1 Eyelid C44.2 External ear C44.3 Skin of other and unspecified parts of face C44.4 Skin of scalp and neck C44.5 Skin of trunk C44.6 Skin of upper limb

More information

Amelanotic melanoma of the skin detailed review of the problem

Amelanotic melanoma of the skin detailed review of the problem of the skin detailed review of the problem Strahil Strashilov 1, Veselin Kirov 2, Angel Yordanov 3, Yoana Simeonova 4 and Miroslava Mihailova 5 1. Department of Plastic Restorative, Reconstructive and

More information

Translating Evidence into Practice: Primary Cutaneous Melanoma Guidelines. Sentinel Lymph Node Biopsy

Translating Evidence into Practice: Primary Cutaneous Melanoma Guidelines. Sentinel Lymph Node Biopsy American Academy of Dermatology 2018 Annual Meeting San Diego, CA, February 17, 2018 Translating Evidence into Practice: Primary Cutaneous Melanoma Guidelines. Sentinel Lymph Node Biopsy Christopher Bichakjian,

More information

1

1 www.clinicaloncology.com.ua 1 Prognostic factors of appearing micrometastases in sentinel lymph nodes in skin melanoma M.N.Kukushkina, S.I.Korovin, O.I.Solodyannikova, G.G.Sukach, A.Yu.Palivets, A.N.Potorocha,

More information

Michael T. Tetzlaff MD, PhD

Michael T. Tetzlaff MD, PhD Update on American Joint Cancer Committee (AJCC) staging system for primary cutaneous melanoma Emphasis on concise and accurate reporting of primary and metastatic melanoma for effective risk stratification

More information

Epithelial Cancer- NMSC & Melanoma

Epithelial Cancer- NMSC & Melanoma Epithelial Cancer- NMSC & Melanoma David Chin MB, BCh, BAO, LRCP, LRCS (Ireland) MCh(MD), PhD (UQ), FRCS, FRACS (Plast) Plastic & Reconstructive Surgeon Visiting Scientist Melanoma Genomic Group & Drug

More information

Sentinel Lymph Node Status is the Most Important Prognostic Factor in Patients With Melanoma of the Scalp

Sentinel Lymph Node Status is the Most Important Prognostic Factor in Patients With Melanoma of the Scalp The Laryngoscope VC 2013 The American Laryngological, Rhinological and Otological Society, Inc. Sentinel Lymph Node Status is the Most Important Prognostic Factor in Patients With Melanoma of the Scalp

More information

Citation for published version (APA): Huismans, A. (2015). Regional aspects of melanoma diagnosis and treatment [S.l.]: [S.n.]

Citation for published version (APA): Huismans, A. (2015). Regional aspects of melanoma diagnosis and treatment [S.l.]: [S.n.] University of Groningen Regional aspects of melanoma diagnosis and treatment Huismans, Annemarleen IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite

More information

Melanoma of the Skin

Melanoma of the Skin 24 Melanoma of the Skin C44.0 Skin of lip, NOS C44.1 Eyelid C44.2 External ear C44.3 Skin of other and unspecified parts of face C44.4 Skin of scalp and neck C44.5 Skin of trunk C44. Skin of upper limb

More information

Research Article Prediction of Sentinel Node Status and Clinical Outcome in a Melanoma Centre

Research Article Prediction of Sentinel Node Status and Clinical Outcome in a Melanoma Centre Skin Cancer Volume 2013, Article ID 904701, 7 pages http://dx.doi.org/10.1155/2013/904701 Research Article Prediction of Sentinel Node Status and Clinical Outcome in a Melanoma Centre Vera Teixeira, 1

More information

Clinical and Pathological Features of Cutaneous Malignant Melanoma: A Retrospective Analysis of 124 Japanese Patients

Clinical and Pathological Features of Cutaneous Malignant Melanoma: A Retrospective Analysis of 124 Japanese Patients Clinical and Pathological Features of Cutaneous Malignant Melanoma: A Retrospective Analysis of 24 Japanese Patients Yoshie Kuno, Kazuyuki Ishihara, Naoya Yamazaki and Kiyoshi Mukai 2 'Dermatology Division

More information

Implications of Progesterone Receptor Status for the Biology and Prognosis of Breast Cancers

Implications of Progesterone Receptor Status for the Biology and Prognosis of Breast Cancers 日大医誌 75 (1): 10 15 (2016) 10 Original Article Implications of Progesterone Receptor Status for the Biology and Prognosis of Breast Cancers Naotaka Uchida 1), Yasuki Matsui 1), Takeshi Notsu 1) and Manabu

More information

PAPER. Prognostic Information From Sentinel Lymph Node Biopsy in Patients With Thick Melanoma

PAPER. Prognostic Information From Sentinel Lymph Node Biopsy in Patients With Thick Melanoma PAPER Prognostic Information From Sentinel Lymph Node Biopsy in Patients With Thick Melanoma Charles R. Scoggins, MD, MBA; Adrianne L. Bowen, MD; Robert C. Martin II, MD, PhD; Michael J. Edwards, MD; Douglas

More information

Histopathology of Melanoma

Histopathology of Melanoma THE YALE JOURNAL OF BIOLOGY AND MEDICINE 48, 409-416 (1975) Histopathology of Melanoma G. J. WALKER SMITH Department ofpathology, Yale University School ofmedicine, 333 Cedar Street, New Haven, Connecticut

More information

Carol Davila University of Medicine and Pharmacy, Bucharest, Romania b

Carol Davila University of Medicine and Pharmacy, Bucharest, Romania b Mædica - a Journal of Clinical Medicine MAEDICA a Journal of Clinical Medicine 2015; 10(3): 226-230 ORIGINAL PAPERS Improving Melanoma Path Reports: the Importance of Histopathological Parameters in Diagnosis

More information

THE NEW ZEALAND MEDICAL JOURNAL

THE NEW ZEALAND MEDICAL JOURNAL THE NEW ZEALAND MEDICAL JOURNAL Journal of the New Zealand Medical Association The incidence and thickness of cutaneous malignant melanoma in New Zealand 1994 2004 Ann Richardson, Lynn Fletcher, Mary Jane

More information

AJCC 8 Implementation January 1, 2018 Melanoma of the Skin. Suraj Venna

AJCC 8 Implementation January 1, 2018 Melanoma of the Skin. Suraj Venna AJCC 8 Implementation January 1, 2018 Melanoma of the Skin Suraj Venna Personalized Medicine AJCC 8 th Edition This Time It s Personal Traditional AJCC (TNM) population-based analyses of large databases

More information

Case Scenario 1 Worksheet. Primary Site C44.4 Morphology 8743/3 Laterality 0 Stage/ Prognostic Factors

Case Scenario 1 Worksheet. Primary Site C44.4 Morphology 8743/3 Laterality 0 Stage/ Prognostic Factors CASE SCENARIO 1 9/10/13 HISTORY: Patient is a 67-year-old white male and presents with lesion located 4-5cm above his right ear. The lesion has been present for years. No lymphadenopathy. 9/10/13 anterior

More information

Assisting diagnosis of melanoma through the noninvasive biopsy of skin lesions

Assisting diagnosis of melanoma through the noninvasive biopsy of skin lesions Assisting diagnosis of melanoma through the noninvasive biopsy of skin lesions Symon D Oyly Cotton Ela Claridge School of Computer Science, The University of Birmingham Birmingham B15 2TT, UK Per Hall

More information

Springer Healthcare. Staging and Diagnosing Cutaneous Melanoma. Concise Reference. Dirk Schadendorf, Corinna Kochs, Elisabeth Livingstone

Springer Healthcare. Staging and Diagnosing Cutaneous Melanoma. Concise Reference. Dirk Schadendorf, Corinna Kochs, Elisabeth Livingstone Concise Reference Staging and Diagnosing Cutaneous Melanoma Dirk Schadendorf, Corinna Kochs, Elisabeth Livingstone Extracted from Handbook of Cutaneous Melanoma: A Guide to Diagnosis and Treatment Published

More information

Clinico-pathological Features of Patients with Melanoma and Positive Sentinel Lymph Node Biopsy: A Single Institution Experience

Clinico-pathological Features of Patients with Melanoma and Positive Sentinel Lymph Node Biopsy: A Single Institution Experience 2015;23(2):122-129 CLINICAL ARTICLE Clinico-pathological Features of Patients with Melanoma and Positive Sentinel Lymph Node Biopsy: A Single Institution Experience Damir Homolak 1, Mirna Šitum 2,3, Hrvoje

More information

Contrast with Australian Guidelines A/Pr Pascale Guitera,

Contrast with Australian Guidelines A/Pr Pascale Guitera, Contrast with Australian Guidelines A/Pr Pascale Guitera, Dermatologist, Sydney University NO CONFLICT OF INTEREST Sydney Melanoma Diagnostic Centre, RPAH 2011 2008 225 pages 16 pages http://www.cancer.org.au/file/healthprofessionals/clinica

More information

Morphological characteristics of the primary tumor and micrometastases in sentinel lymph nodes as a predictor of melanoma progression

Morphological characteristics of the primary tumor and micrometastases in sentinel lymph nodes as a predictor of melanoma progression Morphological characteristics of the primary tumor and micrometastases in sentinel lymph nodes as a predictor of melanoma progression M.N. Kukushkina, S.I. Korovin, O.I. Solodyannikova, G.G. Sukach, A.Yu.

More information

Melanoma Surgery Update James R. Ouellette, DO FACS Premier Health Cancer Institute Wright State University Chief, Surgical Oncology Division

Melanoma Surgery Update James R. Ouellette, DO FACS Premier Health Cancer Institute Wright State University Chief, Surgical Oncology Division Melanoma Surgery Update 2018 James R. Ouellette, DO FACS Premier Health Cancer Institute Wright State University Chief, Surgical Oncology Division Surgery for Melanoma Mainstay of treatment for potentially

More information

Clinical Pathological Conference. Malignant Melanoma of the Vulva

Clinical Pathological Conference. Malignant Melanoma of the Vulva Clinical Pathological Conference Malignant Melanoma of the Vulva History F/48 Chinese Married Para 1 Presented in September 2004 Vulval mass for 2 months Associated with watery and blood stained discharge

More information

Collaborative Stage for TNM 7 - Revised 07/14/2009 [ Schema ]

Collaborative Stage for TNM 7 - Revised 07/14/2009 [ Schema ] MelanomaSkin CS Tumor Size Collaborative Stage for TNM 7 - Revised 07/14/2009 [ Schema ] Code 000 No mass/tumor found Description 001-988 001-988 millimeters (code exact size in millimeters) 989 989 millimeters

More information

Sentinel Lymph Node Biopsies in Cutaneous Melanoma: A systematic review of the literature. Sasha Jenkins

Sentinel Lymph Node Biopsies in Cutaneous Melanoma: A systematic review of the literature. Sasha Jenkins Sentinel Lymph Node Biopsies in Cutaneous Melanoma: A systematic review of the literature By Sasha Jenkins A Master s Paper submitted to the faculty of the University of North Carolina at Chapel Hill in

More information

Prognostic Significance of Grading and Staging Systems using MIB-1 Score in Adult Patients with Soft Tissue Sarcoma of the Extremities and Trunk

Prognostic Significance of Grading and Staging Systems using MIB-1 Score in Adult Patients with Soft Tissue Sarcoma of the Extremities and Trunk 843 Prognostic Significance of Grading and Staging Systems using MIB-1 Score in Adult Patients with Soft Tissue Sarcoma of the Extremities and Trunk Tadashi Hasegawa, M.D. 1 Seiichiro Yamamoto, Ph.D. 2

More information

Cutaneous Melanoma: Epidemiology (USA) The Sentinel Node in Head and Neck Melanoma. Cutaneous Melanoma: Epidemiology (USA)

Cutaneous Melanoma: Epidemiology (USA) The Sentinel Node in Head and Neck Melanoma. Cutaneous Melanoma: Epidemiology (USA) The Sentinel Node in Head and Neck Melanoma Cutaneous Melanoma: Epidemiology (USA) 6 th leading cause of cancer among men and women 68,720 new cases of invasive melanoma in 2009 8,650 deaths from melanoma

More information

> 6000 Mutations in Melanoma. Tests That Cay Be Employed. FISH for Additions/Deletions. Comparative Genomic Hybridization

> 6000 Mutations in Melanoma. Tests That Cay Be Employed. FISH for Additions/Deletions. Comparative Genomic Hybridization Winter Clinical 2017: The Assessment and Diagnosis of Melanoma Whitney A. High, MD, JD, MEng Associate Professor, Dermatology & Pathology Director of Dermatopathology (Dermatology) University of Colorado

More information

Melanoma Quality Reporting

Melanoma Quality Reporting Melanoma Quality Reporting September 1, 2013 December 31, 2016 Laurence McCahill, MD Surgical Oncologist Metro Health Surgical Oncology Metro Health Professional Building 2122 Health Drive SW Wyoming,

More information

Surgical Margins in Cutaneous Melanoma (2 cm Versus 5 cm for Lesions Measuring Less Than 2.1-mm Thick)

Surgical Margins in Cutaneous Melanoma (2 cm Versus 5 cm for Lesions Measuring Less Than 2.1-mm Thick) 1941 Surgical Margins in Cutaneous Melanoma (2 cm Versus 5 cm for Lesions Measuring Less Than 2.1-mm Thick) Long-Term Results of a Large European Multicentric Phase III Study David Khayat, M.D., Ph.D.

More information

We are IntechOpen, the world s leading publisher of Open Access books Built by scientists, for scientists. International authors and editors

We are IntechOpen, the world s leading publisher of Open Access books Built by scientists, for scientists. International authors and editors We are IntechOpen, the world s leading publisher of Open Access books Built by scientists, for scientists 3,500 108,000 1.7 M Open access books available International authors and editors Downloads Our

More information

Update on SLN and Melanoma: DECOG and MSLT-II. Gordon H. Hafner, MD, FACS

Update on SLN and Melanoma: DECOG and MSLT-II. Gordon H. Hafner, MD, FACS Update on SLN and Melanoma: DECOG and MSLT-II Gordon H. Hafner, MD, FACS No disclosures The surgery of malignant disease is not the surgery of organs, it is of the lymphatic system. Lord Moynihan Lymph

More information

Measurement of c-myc oncogene expression provides an accurate prognostic marker for acral lentiginous melanoma

Measurement of c-myc oncogene expression provides an accurate prognostic marker for acral lentiginous melanoma British Journal of Plastic Surgery (1999), 52, 122 126 1999 The British Association of Plastic Surgeons Measurement of c-myc oncogene expression provides an accurate prognostic marker for acral lentiginous

More information

Cover Page. The handle holds various files of this Leiden University dissertation

Cover Page. The handle   holds various files of this Leiden University dissertation Cover Page The handle http://hdl.handle.net/1887/55957 holds various files of this Leiden University dissertation Author: Dekker T.J.A. Title: Optimizing breast cancer survival models based on conventional

More information

Prognosis of Sentinel Node Staged Patients with Primary Cutaneous Melanoma

Prognosis of Sentinel Node Staged Patients with Primary Cutaneous Melanoma Prognosis of Sentinel Node Staged Patients with Primary Cutaneous Melanoma Otmar Elsaeßer 1., Ulrike Leiter 1 *., Petra G. Buettner 2, Thomas K. Eigentler 1, Friedegund Meier 1, Benjamin Weide 1, Gisela

More information

Melanoma Patients and the Sentinel Lymph Node (SLN) Procedure: An Oncologic Surgeon s Perspective

Melanoma Patients and the Sentinel Lymph Node (SLN) Procedure: An Oncologic Surgeon s Perspective Melanoma Patients and the Sentinel Lymph Node (SLN) Procedure: An Oncologic Surgeon s Perspective Giorgos C. Karakousis, M.D. Associate Professor of Surgery Hospital of the University of Pennsylvania Disclosures

More information

ORIGINAL ARTICLE. Predicting the Prognosis of Oral Squamous Cell Carcinoma After First Recurrence

ORIGINAL ARTICLE. Predicting the Prognosis of Oral Squamous Cell Carcinoma After First Recurrence ORIGINAL ARTICLE Predicting the Prognosis of Oral Squamous Cell Carcinoma After First Recurrence Michael D. Kernohan, FDSRCS, FRCS, MSc; Jonathan R. Clark, FRACS; Kan Gao, BEng; Ardalan Ebrahimi, FRACS;

More information

47. Melanoma of the Skin

47. Melanoma of the Skin 1 Terms of Use The cancer staging form is a specific document in the patient record; it is not a substitute for documentation of history, physical examination, and staging evaluation, or for documenting

More information

Advances in Surgical Management of Primary Melanoma: Identifying Patients Who Need More than Conventional Wide Local Excision

Advances in Surgical Management of Primary Melanoma: Identifying Patients Who Need More than Conventional Wide Local Excision Advances in Surgical Management of Primary Melanoma: Identifying Patients Who Need More than Conventional Wide Local Excision Christopher J. Miller, MD Director of Penn Dermatology Oncology Center Associate

More information

Perigastric lymph node metastases in gastric cancer: comparison of different staging systems

Perigastric lymph node metastases in gastric cancer: comparison of different staging systems Gastric Cancer (1999) 2: 201 205 Original article 1999 by International and Japanese Gastric Cancer Associations Perigastric lymph node metastases in gastric cancer: comparison of different staging systems

More information

NAACCR Webinar Series 1

NAACCR Webinar Series 1 Collecting Cancer Data: Melanoma 2013 2014 NAACCR Webinar Series April 3, 2014 Q&A Please submit all questions concerning webinar content through the Q&A panel. Reminder: If you have participants watching

More information

The Clinical Significance of Tumor-Infiltrating Lymphocytes and Microscopic Satellites in Acral Melanoma in a Korean Population

The Clinical Significance of Tumor-Infiltrating Lymphocytes and Microscopic Satellites in Acral Melanoma in a Korean Population Clinical Significance of TIL and Ms in Korean Acral Melanoma Ann Dermatol Vol. 25, No. 1, 2013 http://dx.doi.org/10.5021/ad.2013.25.1.61 ORIGINAL ARTICLE The Clinical Significance of Tumor-Infiltrating

More information

Citation for published version (APA): Francken, A. B. (2007). Primary and metastatic melanoma: aspects of follow-up and staging s.n.

Citation for published version (APA): Francken, A. B. (2007). Primary and metastatic melanoma: aspects of follow-up and staging s.n. University of Groningen Primary and metastatic melanoma Francken, Anne Brecht IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check

More information

CUTANEOUS MALIGNANT MELANOMA IN SWEDISH CHILDREN AND TEENAGERS : A CLINICO-PATHOLOGICAL STUDY OF 130 CASES

CUTANEOUS MALIGNANT MELANOMA IN SWEDISH CHILDREN AND TEENAGERS : A CLINICO-PATHOLOGICAL STUDY OF 130 CASES Int. J. Cancer: 80, 646 65 (999) 999 Wiley-Liss, Inc. Publication of the International Union Against Cancer Publication de l Union Internationale Contre le Cancer CUTANEOUS MALIGNANT MELANOMA IN SWEDISH

More information

Table of contents. Page 2 of 40

Table of contents. Page 2 of 40 Page 1 of 40 Table of contents Introduction... 4 1. Background Information... 6 1a: Referral source for the New Zealand episodes... 6 1b. Invasive and DCIS episodes by referral source... 7 1d. Age of the

More information

Sentinel Lymph Node Biopsy in Patients With Thin Melanoma

Sentinel Lymph Node Biopsy in Patients With Thin Melanoma STUDY Sentinel Lymph Node Biopsy in Patients With Thin Melanoma Julie B. Lowe, MD; Eva Hurst, MD; Jeffrey F. Moley, MD; Lynn A. Cornelius, MD Objective: To define the percentage of positive sentinel lymph

More information

Radiotherapy and Conservative Surgery For Merkel Cell Carcinoma - The British Columbia Cancer Agency Experience

Radiotherapy and Conservative Surgery For Merkel Cell Carcinoma - The British Columbia Cancer Agency Experience Radiotherapy and Conservative Surgery For Merkel Cell Carcinoma - The British Columbia Cancer Agency Experience Poster No.: RO-0003 Congress: RANZCR FRO 2012 Type: Scientific Exhibit Authors: C. Harrington,

More information

World Articles of Ear, Nose and Throat Page 1

World Articles of Ear, Nose and Throat Page 1 World Articles of Ear, Nose and Throat ---------------------Page 1 Primary Malignant Melanoma of the Tongue: A Case Report Authors: Nanayakkara PR*, Arudchelvam JD** Ariyaratne JC*, Mendis K*, Jayasekera

More information

12. Malignant Melanoma of Skin

12. Malignant Melanoma of Skin KEY FACTS 12. Malignant Melanoma of Skin ICD-9 172 On average 160 melanomas of the skin were registered per year. Twice as common in females than in males. Higher than expected numbers in Southern Board

More information